pegyl interferon alfaa sell brand name pegasi among medic use treat hepat hepat hepat typic use togeth ribavirin cure rate hepat may use alon give inject skin side effect common may includ headach feel tire depress troubl sleep hair loss nausea pain site inject fever sever side effect may includ psychosi autoimmun disord blood clot infect use ribavirin recommend pregnanc pegyl interferon alfaa alpha interferon famili medic pegyl protect molecul breakdown pegyl interferon alfaa approv medic use unit state world health organ list essenti medicin drug approv around world treatment chronic hepat includ peopl hiv coinfect cirrhosi normal level alt recent approv eu china mani countri treatment chronic hepat also use treatment certain tcell lymphoma particular mycosi fungoid peginterferon alfaa long act interferon interferon protein releas bodi respons viral infect interferon import fight virus bodi regul reproduct cell regul immun system genotyp hepat treat pegyl interferon alfaa pegyl interferon alfab combin ribavirin show genet polymorph near human ilb gene encod interferon lambda associ signific differ respons treatment find origin report natur show genotyp hepat patient carri certain genet variant allel near ilb gene like achiev sustain virolog respons treatment anoth report natur demonstr genet variant also associ natur clearanc genotyp hepat virus also use middl east respiratori syndrom hepat pegyl branch kgmol peg chain drug manufactur brand name pegasi roch pharmaceut due chang clinic practic antivir hepat drug sofosbuvir becom much import roch announc would withdraw pegasi market worldwid subsequ sell worldwid right pharma austrian swiss pharmaceut compani ensur suppli medium long term almost worldwid exclud china japan cochran review seek determin whether interferon alfaa could use treatment individu neovascular agerel macular degener find evid improv visual acuiti potenti harm